Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

Abstract Background Recurrence of cancer after curative surgery is a major problem after most cancer treatments. Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis. Recent studies showed...

Full description

Bibliographic Details
Main Authors: Haruko Yamamoto, Toshimitsu Hamasaki, Kaori Onda, Takashi Nojiri, Masato Aragaki, Nao Horie, Norihiro Sato, Yasuhiro Hida
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Trials
Subjects:
Beta-blocker
Cancer recurrence
Clinical trial
Lung cancer
Landiolol
Online Access:https://doi.org/10.1186/s13063-019-3904-4

Internet

https://doi.org/10.1186/s13063-019-3904-4

Similar Items